Axa
HRMY icon

Axa’s Harmony Biosciences HRMY Stock Holding History

Axa’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-82,907
Closed -$2.62M – 526
2025
Q2 		$2.62M Buy
82,907
+5,756
+7% +$185K 0.01% 715
2025
Q1 		$2.56M Buy
77,151
+35,680
+86% +$1.28M 0.01% 691
2024
Q4 		$1.43M Buy
41,471
+4,707
+13% +$162K ﹤0.01% 821
2024
Q3 		$1.47M Hold
36,764
– – ﹤0.01% 810
2024
Q2 		$1.11M Sell
36,764
-856
-2% -$25.7K ﹤0.01% 861
2024
Q1 		$1.26M Buy
37,620
+30,020
+395% +$964K ﹤0.01% 816
2023
Q4 		$245K Buy
+7,600
New +$212K ﹤0.01% 1016

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Axa's HRMY Position: Q3 2025 in Review

Axa sold out of Harmony Biosciences (HRMY) in Q3 2025, closing a stake of 82,907 shares — an estimated $2.62M sold.

Axa first reported a position in HRMY in Q4 2023 and held it in 7 quarters. The position peaked at $2.62M in Q2 2025. 296 funds tracked by Wall St. Rank hold HRMY as of Q3 2025.

  • Axa reported no remaining Harmony Biosciences position as of Q3 2025 after selling out during the quarter.
  • Axa sold 82,907 Harmony Biosciences shares in Q3 2025, an estimated $2.62M.
  • Axa first reported a position in Harmony Biosciences in Q4 2023 and held it in 7 quarters.
  • Axa's Harmony Biosciences position peaked at $2.62M in Q2 2025.
  • 296 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.